

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Syngene announces plans to add bioconjugation suite for end-to-end ADC development

23 October 2025 | News

Bioconjugation capability will complement commercial payload, linker and monoclonal antibodies services



Syngene International, a global contract research, development and manufacturing organization (CRDMO), is adding a GMP bioconjugation suite at its commercial biologics facility [Unit 3] in Bengaluru.

With this new capability, Syngene will offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs) – from discovery through to GMP manufacturing – placing it among a handful of CDMOs with full-service capabilities.

The OEB-5 rated suite will accelerate ADC development timelines by enabling both Monoclonal Antibodies (mAb) production and GMP bioconjugation at a single site, complementing Syngene's existing commercial capabilities in payload and linker manufacturing. Expected to be operational within this financial year, the conjugation facility will also support a range of advanced conjugates and related modalities. These services are further strengthened by collocated analytical and bioanalytical capabilities, ensuring seamless integration across the development lifecycle.

"The discovery and development of ADCs is complex, often involving multiple vendors and geographically dispersed sites, which adds substantial supply chain complexity and potential delays," said Alex Del Priore, Head - LM CDMO, Syngene International. "By integrating bioconjugation capabilities with our commercial-scale biologics, payload, and linker production units in Bengaluru, we can significantly compress development timelines and offer a unique, end-to-end pathway from early discovery through to GMP manufacturing," he added.

Building on a decade of experience in ADC discovery and with proven expertise in handling high-potency payloads, linkers, and mAbs across well-established, GMP-compliant facilities, Syngene is scaling its capabilities to support clinical programs and plans to develop commercial-scale capabilities in the future.

Additionally, the laboratories will offer process development, analytical characterisation, and scale-up for both early- and late-stage programmes.